Clinical Trials Logo
  1. Home
  2. Multiple Sclerosis (MS)
  3. NCT04121468

A Phase I Double Blind Study of Metformin Acting on Endogenous Neural Progenitor Cells in Children With Multiple Sclerosis

Multiple Sclerosis (MS) Clinical Trial

Official title:
A Phase I Double Blind Study of Metformin Acting on Endogenous Neural Progenitor Cells in Children With Multiple Sclerosis

Clinical Trial Summary

A randomized multiple baseline feasibility trial where participants will start taking metformin at one of 3 randomly determined points (3-months, 6-months or 9 months) during the 12-month trial. All subjects will be on a daily dose of metformin for a minimum of 3 months and a maximum of 9 months.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04121468
Study type Interventional
Source The Hospital for Sick Children
Contact E. Ann Yeh, MA, MD, FRCPC, Dip ABPN
Phone 416-813-7353
Email ann.yeh@sickkids.ca
Status Recruiting
Phase Phase 1/Phase 2
Start date February 24, 2020
Completion date December 2023
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05177523 - Imaging the Interplay Between Axonal Damage and Repair in Multiple Sclerosis
Not yet recruiting NCT06053749 - An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden
Not yet recruiting NCT06450600 - Enhancing Quality of Life in MS Patients Through Tailored Therapeutic Education N/A
Recruiting NCT04926818 - Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis Phase 3
Not yet recruiting NCT03624296 - Characterization of Cortical Injury in Early MS Patients: a 7T MRI Study N/A
Terminated NCT04203498 - Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple Sclerosis Phase 3
Active, not recruiting NCT04602390 - Assessment of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis Phase 1
Completed NCT01804647 - Longitudinal Therapeutically Non-interventional Study of MSRV-Env Burden in Patients With Multiple Sclerosis Disease
Terminated NCT04907305 - Next-Gen MS: Feed-forward PRO Data for MS Research
Active, not recruiting NCT03456206 - Chronic Inflammatory Disease, Lifestyle and Risk of Disease
Completed NCT04705610 - Social Cognition in Multiple Sclerosis, From a Study of Eye Movement and Gaze Strategies Using Video-oculography N/A
Completed NCT01366027 - PRISM Registry: Pseudobulbar Affect Registry Series N/A
Completed NCT03135249 - Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple Sclerosis Phase 4
Recruiting NCT05633875 - Multimodal Imaging Signatures of the Biological Mechanisms Underlying Neurodegeneration in Multiple Sclerosis
Completed NCT02612935 - An Observational Pilot Study of Lumosity Computerized Cognitive Training in Subjects With Multiple Sclerosis N/A
Completed NCT02739542 - Assessment of Tecfidera® in Radiologically Isolated Syndrome (RIS) Phase 4
Completed NCT03177655 - Effect of Guided Imagery on Well-being in Patients With Multiple Sclerosis N/A
Active, not recruiting NCT04777539 - Comparing the Safety and Benefit of Natalizumab (Tysabri®) At-home Infusion vs At-hospital Infusion in Multiple Sclerosis
Recruiting NCT02352194 - Physical Capacity and Rehabilitation of Patients With Multiple Sclerosis N/A
Completed NCT02308579 - Centralized Reading Assessment of Chronic CerebroSpinal Venous Insufficiency (CCSVI) in Patients With Multiple Sclerosis and Other Neurological Diseases N/A